Lewy bodies and response to tacrine in Alzheimer's disease.
about
Cholinesterase inhibition in Parkinson's diseaseDementia with Lewy bodies.Dementia with Lewy bodies: diagnosis and management.Successful use of donepezil for the treatment of dementia with Lewy bodies.Donepezil: a clinical review of current and emerging indications.Analysis of the substantia innominata volume in patients with Parkinson's disease with dementia, dementia with lewy bodies, and Alzheimer's diseaseApolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease.Dementia with Lewy bodies: review and pharmacotherapeutic implications.Lewy body dementia.Pharmacotherapy of behavioral and psychological symptoms of dementia: time for a different paradigm?The new Qualitative Scoring MMSE Pentagon Test (QSPT) as a valid screening tool between autopsy-confirmed dementia with Lewy bodies and Alzheimer's disease.Pharmacotherapy of dementia with Lewy bodies.Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies.Imaging and acetylcholinesterase inhibitor response in dementia with Lewy bodies.Treatment of dementia with lewy bodiesThe Italian dementia with Lewy bodies study group (DLB-SINdem): toward a standardization of clinical procedures and multicenter cohort studies design.Tacrine and lecithin in Alzheimer's disease. Patient heterogeneity explains varied response.Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study.Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial.A comparison of episodic memory deficits in neuropathologically-confirmed Dementia with Lewy bodies and Alzheimer's disease.Atrophy of the cholinergic basal forebrain in dementia with Lewy bodies and Alzheimer's disease dementia.Efficacy and safety of donepezil in patients with dementia with Lewy bodies: preliminary findings from an open-label study.Differences in survival between patients with dementia with Lewy bodies and patients with Alzheimer's disease--measured from a fixed cognitive level.Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial.
P2860
Q28870519-656CF01F-1237-4A78-8D20-17B05DA0492FQ30586107-C905E9B1-D7A4-4D06-B9C5-E445018675E2Q30667144-C3582F0D-99D8-4D58-A02E-79166C38B12EQ32052939-A8EB5E2C-3F06-4E99-A640-CB41DFE13FD9Q33150809-F8E05A8A-5146-47A6-8DD7-0A0DB87AA8E9Q33636322-05C46E20-02A8-4835-9105-60F137F03753Q33662063-73853009-E4F4-49B0-AB87-40E6FDFC5809Q33693803-029E7B4B-9CC2-4D6D-AD0E-5AF53485B54CQ33708670-7C8E0A13-710E-4669-861F-85A72F9574D6Q34146983-BA04E94C-0C6C-4B35-8C23-FF05F56C9E4AQ35136912-6BD5B69B-2CE6-428F-B4D9-34D9E30ABDE1Q35574995-7E6560A5-A1A1-4705-86C8-46B3C5AF0D32Q35863422-A656F598-3B4B-4D96-A426-E2611778FF5FQ36124416-27CF7420-46DC-41F0-92BD-02E50FFF941DQ37552865-DE82258D-B078-48C6-B890-3BC24F054647Q38821557-25063B8E-5AF1-4A3A-ACE7-F24E6F6C1234Q42582193-E76BB430-4D85-4DF9-AE87-706E22682D9BQ43460562-C96F8BC5-5CAA-4307-87E4-8A7D5C30F164Q43827133-C3EAF61F-0CE4-4983-A9F2-69253503CCDEQ45982741-E549FCE6-7BA0-45C9-9BF9-648A8EB97EC8Q48639125-64F58B21-D5CD-4B6A-886E-59DDC9AD519BQ50113462-D09B654B-BE4C-4054-BC82-853FE3B449E6Q50769270-951A6642-6A40-4C1B-B4F1-EAAC0E05D544Q53911489-F7FDE97F-3FF4-454C-AD49-81FBD66E6756
P2860
Lewy bodies and response to tacrine in Alzheimer's disease.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
1994年學術文章
@zh-hant
name
Lewy bodies and response to tacrine in Alzheimer's disease.
@en
Lewy bodies and response to tacrine in Alzheimer's disease.
@nl
type
label
Lewy bodies and response to tacrine in Alzheimer's disease.
@en
Lewy bodies and response to tacrine in Alzheimer's disease.
@nl
prefLabel
Lewy bodies and response to tacrine in Alzheimer's disease.
@en
Lewy bodies and response to tacrine in Alzheimer's disease.
@nl
P2093
P1433
P1476
Lewy bodies and response to tacrine in Alzheimer's disease.
@en
P2093
M Griffiths
P356
10.1016/S0140-6736(94)90966-0
P407
P577
1994-01-01T00:00:00Z